WO2008020743A2 - Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis - Google Patents

Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis Download PDF

Info

Publication number
WO2008020743A2
WO2008020743A2 PCT/MN2006/000005 MN2006000005W WO2008020743A2 WO 2008020743 A2 WO2008020743 A2 WO 2008020743A2 MN 2006000005 W MN2006000005 W MN 2006000005W WO 2008020743 A2 WO2008020743 A2 WO 2008020743A2
Authority
WO
WIPO (PCT)
Prior art keywords
buffer
tris hcl
column
poison
hcl buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MN2006/000005
Other languages
English (en)
Russian (ru)
Other versions
WO2008020743A3 (fr
Inventor
Georgiy Volkov
Alexiy Savchuk
Vitaly Karbovskyy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WISDOM ASSET Co
Original Assignee
WISDOM ASSET Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WISDOM ASSET Co filed Critical WISDOM ASSET Co
Publication of WO2008020743A2 publication Critical patent/WO2008020743A2/fr
Publication of WO2008020743A3 publication Critical patent/WO2008020743A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to the industry of bioactive substances and can be used in biotechnological industries, medicine and the pharmaceutical industry, namely the production of medicines and diagnostic preparations from snake venom.
  • a platelet aggregation inhibitor is a protein that has an inhibitory effect on the platelet activation process by various activation agents.
  • platelet activation inhibitors There are a significant number of platelet activation inhibitors from various sources. All of them differ in the strength of inhibition and the mechanisms by which this inhibition is carried out.
  • One of the effective sources of platelet activation inhibitors is snake venoms, which contain only protein components and have a stable composition.
  • Some methods for producing active enzymes from snake venom are known.
  • a method is known for producing active enzymes from the snake venom of Triteresir okppaepsis by fractionation of poisoned with buffer on Sephadex G-100, chromatography on SM-Touorerl 650M in two stages and final purification on Mono Q gel.
  • Purificapofepofitofibf -Race spake (Agistrodop asites) venom., Toxicon.-1999.-V.37, N7.-P.999-1013); from Yard Agcistrodop Asitis, in which the poison dissolved in the buffer is subjected to separation of the DEAE Sephadex A-50 anion exchanger, then chromatographed twice on Sephadex G-200 (Quaupg C, Hong J. et al. Aspirates Vpom apd its comraritiop with bovipe tlombip., Thromb.Diath.haymorrth. -1971.
  • a method for isolating snake venom of platelet aggregation PAl is proposed, the essence of which includes a method for determining the ability to inhibit platelet aggregation in snake venom, a method for purifying an inhibitor of platelet activity from various samples of snake venom, its characterization and a truncated form containing a modified lysine residue that specifically inhibits fibrin binding or von Willebrand factor with GPPb-Sha. (WO 90/15620, 06/16/1989, Platellet agregatiphibitors, COR ⁇ S, INC).
  • the disadvantage of the prototype is both a low level of profitability of the production process, a low level of purity and a large investment of time.
  • the basis of the invention is the task to develop a method for isolating a platelet activation inhibitor from Agkistrodop Yothqffii poison syriepsis poison, which allows by means of affinity chromatography followed by ion exchange chromatography and the use of carriers with higher chromatographic properties and physicochemical stability to increase the profitability of the production process and reduce the isolation time / fibrinoliptic protein and increase its purity.
  • the problem is solved in a method of an inhibitor of platelet activation from the Agkistrodop Yothoffii venereus poison in that affinity chromatography is carried out on a column with a carrier of Clin Serharose FF using 1OmM Tris HCl with pH 7.4 as a buffer solution.
  • the fraction of a material unrelated to Blue Serum FF was diluted 8 times with 5OmM Tris HCl buffer with pH 8.2 and applied to a column filled with DEAE Serophoros FF anion exchanger, previously equilibrated with 5OmM Tris HCl buffer with pH 8.2.
  • the platelet activation inhibitor was eluted with 5OmM Tris HCl buffer at pH 8.2 with a content of 0.2M NaCl.
  • the protein peak containing the platelet activation inhibitor is collected, concentrated, and applied to replace the buffer with a Serhadex G25 column equilibrated with 5OmM Tris HCl buffer with a pH of 7.4 containing 0.1 ZM NaCl.
  • the problem is solved by the proposed method, when the parameters of the process of isolation of platelet activation inhibitorg are in the ranges indicated in the claims. When the parameters are changed in the direction of increasing or decreasing, the characteristics of the resulting preparation worsen.
  • the solution of the poison is applied to a column (C 10/10, volume 7 ml) with an affinity sorbent Vlie Serharose FF, previously equilibrated with 50 ml of 1OmM Tris HCl buffer with a pH of 7.4 (column equilibration rate of 2 ml / min, poison application rate 0.5 ml / min ) After application, 1OmM Tris HCl buffer with a pH of 7.4 is passed through the column at a speed of 2 ml / min and all unbound material (60 ml) is collected.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • the fraction of material unrelated to Vlhe Serofaros FF was diluted 8 times with 5OmM Tris HCl with a pH 8.2 buffer and applied to a column filled with DEAE Serocos FF anion exchanger (column size Ix8cm, volume 7ml), pre-equilibrated with 5OmM Tris HCl 2 buffered with a pH of 2 buffered with 2 buffered with a pH of 2 buffered with 8.2 buffer min (Sample application speed lml / min). The bulk of the proteins (85%) are collected on the anion exchanger.
  • the platelet activation inhibitor is eluted with a stepwise gradient of ionic strength 0.2M NaCl in 5OmM Tris HCl buffer with pH 8.2 at a rate of 2 ml / min.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • a protein peak containing a platelet activation inhibitor is collected (6 ml) and dried by lyophilization. Characteristic Yield, mg 2.0 mg (4.2%)
  • the solution of the poison is applied to a column (C 10/10, volume 7 ml) with an affinity sorbent Vlie Serharose FF, previously equilibrated with 50 ml of 1OmM Tris HCl buffer with a pH of 7.4 (column equilibration rate of 2 ml / min, poison application rate 0.5 ml / min )
  • 1OmM Tris HCl buffer with a pH of 7.4 is passed through the column at a speed of 2 ml / min and all unbound material (53 ml) is collected.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • the fraction of material unrelated to Vlhe Serofaros FF was diluted 8 times with 5OmM Tris HCl with a pH 8.2 buffer and applied to a column filled with DEAE Serocos FF anion exchanger (column size Ix8cm, volume 7ml), pre-equilibrated with 5OmM Tris HCl 2 buffered with a pH of 2 buffered with 2 buffered with a pH of 2 buffered with 8.2 buffer min (Sample application speed lml / min). The bulk of the proteins (85%) are collected on the anion exchanger.
  • the platelet activation inhibitor is eluted with a stepwise gradient of ionic strength of 0.2 M NaCl in 5OmM Tris HCl buffer with pH 8.2 at a rate of 2 ml / min.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • the protein peak containing the platelet activation inhibitor is collected (5.2 ml) and dried by lyophilization. Characteristic Yield, mg 1.7 mg (3.9%) Biological activity IC 5O 232nM
  • the solution of the poison is applied to a column (CU / 10, volume 7 ml) with an affinity sorbent Vlie Serharose FF, previously equilibrated with 50 ml of 1OmM Tris HCl buffer with a pH of 7.4 (column equilibration rate of 2 ml / min, poison application rate of 0.5 ml / min).
  • 1OmM Tris HCl buffer with pH 7.4 is passed through the column at a speed of 2 ml / min and all material unbound with the sorbent (75 ml) is collected.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • the fraction of material unrelated to Vlhe Serofaros FF was diluted 8 times with 5OmM Tris HCl with a pH 8.2 buffer and applied to a column filled with DEAE Serocos FF anion exchanger (column size Ix8cm, volume 7ml), pre-equilibrated with 5OmM Tris HCl 2 buffered with a pH of 2 buffered with 2 buffered with a pH of 2 buffered with 8.2 buffer min (Sample application speed lml / min). The bulk of the proteins (85%) are collected on the anion exchanger.
  • the platelet activation inhibitor is eluted with a stepwise gradient of ionic strength 0.2M NaCl in 5OmM Tris HCl buffer with pH 8.2 at a rate of 2 ml / min.
  • the optical density was recorded continuously using a flow monitor REC 102 (Parmacia biotech).
  • a protein peak containing a platelet activation inhibitor is collected (7.1 ml) and dried by lyophilization.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la production de substances bioactives, et peut être utilisée dans des processus de production biotechnologiques, en médecine et dans l'industrie pharmaceutique, en particulier pour produire des préparations médicinales et diagnostiques à partir de venin de serpent. Le procédé selon l'invention est caractérisé en ce qu'il consiste : à effectuer une chromatographie d'affinité sur une colonne contenant un support Blue Sepharose FF, à l'aide d'une solution tampon se présentant sous la forme de Tris HCl présentant un pH de 7,4, puis à diluer huit fois la fraction du matériau non conjugué à Blue Sepharose FF à l'aide d'une solution tampon de Tris HCl présentant un pH de 8,2, et à appliquer sur une colonne remplie d'un échangeur d'anions de DEAE Sepharose FF et préalablement équilibrée par la solution tampon de Tris HCl; puis à laver le sorbant pour éliminer le matériau non conjugué, à éluer un inhibiteur de l'activation plaquettaire dans la solution tampon de Tris HCl contenant du NaCl, à recueillir et à concentrer le pic protéique contenant l'inhibiteur de l'activation plaquettaire, à l'appliquer, afin de remplacer la solution tampon, sur une colonne Sephadex G25 équilibrée par la solution tampon de HCl contenant du NaCl, età procéder enfin à un séchage par lyophilisation.
PCT/MN2006/000005 2006-08-16 2006-08-30 Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis Ceased WO2008020743A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MN381206 2006-08-16
MN3812 2006-08-16

Publications (2)

Publication Number Publication Date
WO2008020743A2 true WO2008020743A2 (fr) 2008-02-21
WO2008020743A3 WO2008020743A3 (fr) 2008-07-10

Family

ID=39082466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MN2006/000005 Ceased WO2008020743A2 (fr) 2006-08-16 2006-08-30 Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis

Country Status (1)

Country Link
WO (1) WO2008020743A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293795A (en) * 1969-07-04 1972-10-25 Twyford Lab Ltd Improvements relating to anticoagulants
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
CN1250718C (zh) * 2002-12-05 2006-04-12 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶的层析纯化方法
RU2271219C1 (ru) * 2004-07-28 2006-03-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Министерства здравоохранения Российской Федерации" Способ получения тромбиноподобных ферментов из яда змеи

Also Published As

Publication number Publication date
WO2008020743A3 (fr) 2008-07-10

Similar Documents

Publication Publication Date Title
Cheng et al. Identification and inhibitory activity against α-thrombin of a novel anticoagulant peptide derived from oyster (Crassostrea gigas) protein
JPS62174023A (ja) 抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤
Hvatum et al. Studies on tissue thromboplastin-Its splitting into two separable parts
Thakur et al. Biochemical and pharmacological characterization of a toxic fraction and its cytotoxin-like component isolated from Russell's viper (Daboia russelii russelii) venom
Babaie et al. Isolation and partial purification of anticoagulant fractions from the venom of the Iranian snake Echis carinatus
ESTBORN Separation of phosphatase isoenzymes by gelfiltration
De-Simone et al. Simple affinity chromatographic procedure to purify β-galactoside binding lectins
Tian et al. Purification and biochemical characterization of a novel fibrinolytic enzyme, PSLTro01, from a medicinal animal Porcellio scaber Latreille
Lee et al. Cloning and characterization of a blood coagulation factor IX-binding protein from the venom of Trimeresurus stejnegeri
WO2014075374A1 (fr) Hémocoagulase-b d'agkistrodon acutus
WO2008020743A2 (fr) Procédé permettant d'extraire un inhibiteur de l'agrégation plaquettaire du venin d'agkistrodon blomhoffii ussuriensis
EP0020780A1 (fr) Materiau fibrinolytique et son procede de fabrication
US4027012A (en) Process for the extraction of components having anticoagulant activity "in vivo" from snake venoms and products obtained
Li et al. Antithrombotic and thrombolytic activities of Agkisacutacin, a snake venom proteinase, in experimental models
Mukherjee et al. Medical and diagnostic applications of snake venom proteomes
Sadeesh Kumar et al. Screening and characterization of fibrinolytic protease producing Bacillus circulans from mangrove sediments Pitchavaram, South East Coast of India
Hanumegowda et al. Kenaf seed cysteine protease (Kscp) inhibits the intrinsic pathway of the blood coagulation cascade and platelet aggregation
WO2008020742A2 (fr) Procédé permettant d'extraire une protéine fibrinogène/fibrinolytique du venin d'agkistrodon blomhoffii ussuriensis
WO2008020739A2 (fr) PROCÉDÉ PERMETTANT D'EXTRAIRE UNE ENZYME DE TYPE THROMBINE α SPÉCIFIQUE DU VENIN D'AGKISTRODON BLOMHOFFII USSURIENSIS
RU2262947C2 (ru) Способ получения тромбиноподобного коагулирующего фермента
JP3878668B2 (ja) 血栓性疾患の治療
KR100447101B1 (ko) 혈전용해작용이 있는 동충하초 추출물 및 이로부터 분리된혈전용해효소
JPH0965879A (ja) 新規血栓溶解酵素とその製造方法
Tan et al. Isolation and characterization of the thrombin-like enzyme from Cryptelytrops albolabris (white-lipped tree viper) venom
WO2008020740A2 (fr) Procédé permettant d'extraire un activateur de la protéine c du venin d'agkistrodon blomhoffii ussuriensis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06799435

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06799435

Country of ref document: EP

Kind code of ref document: A2